首页> 外文OA文献 >Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial

【2h】

Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial

机译：在全球Napoli-1期III试验中，选定脂质体IRINOTECAN（NAL-IRI）的脂质体IRINOTECAN（NAL-IRI）分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
T. Macarulla Mercadé; K. Lee; G. Lakatos; A. Wang-Gillam; L. Chen; B. Mirakhur; F. De Jong;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial (vol 49, pg 62, 2020) [J] . Pancreas . 2020 ,第3期

机译：脂质体Irinotecan + 5-Fu / LV在转移性胰腺癌中：患者，肿瘤和先前治疗特征的亚组分析在枢轴中的Napoli-1试验中（Vol 49，PG 62,2020）
2. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial [J] . Macarulla Teresa, Blanc Jean-Frederic, Wang-Gillam Andrea, Journal of geriatric oncology . 2019 ,第3期

机译：脂质体Irinotecan和5-氟尿嘧啶/ Leucovorin在老年转移性胰腺癌患者中 - 一种枢轴Napoli-1试验的亚组分析
3. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial [J] . Chen Li-Tzong, Siveke Jens T., Wang-Gillam Andrea, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018 ,第期

机译：与NAL-IRI（脂质体IRINOTECAN）加上5-氟尿嘧啶和白瓜和Leucovorin的生存，每方例和NAPOLI-1的非每组议程种群：对全球第3阶段试验的扩展分析
4. PD-023Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy [O] . L.-T. Chen, J. Siveke, A. Wang-Gillam, -1

机译：PD-023 NAPOLI-1中各亚组之间的安全性：先前在转移性胰腺癌（mPAC）中对nal-IRI（MM-398）±5-氟尿嘧啶和亚叶酸钙（5-FU / LV）与5-FU / LV进行的3期研究吉西他滨治疗
5. 242P Effects of nal-IRI (MM-398) 6 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1 [O] . R. Hubner, A. Cubillo, J.-F. Blanc, 2016

机译：NAL-IRI（MM-398）的242P效应于先前用吉西他滨治疗治疗的转移性胰腺导管腺癌（MPDAC）患者的寿命质量（QOL）的影响：Napoli-1的结果

Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial

著录项

相似文献

相关主题

期刊订阅